Pharma Packaging
-
Upload
supernimish -
Category
Documents
-
view
225 -
download
0
description
Transcript of Pharma Packaging
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 1/29
Opportunities and Challenges
for Pharmaceutical SupplyChains in India: A Case
BY
Dr. RA!S" #$%AR SI&'"
Associate Professor
Delhi (echnological $ni)ersity *DC!+, Delhi
1
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 2/29
Plan of Presentation
• Introduction of PharmaceuticalIndustry
• Critical issues
• Pressures and Challenges
• Case Study
• Supply Chain PerformanceFramework
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 3/29
Introduction• The pharmaceutical industry can be dened as a combination
of processes, organizations and operations inoled in thedeelopment, design and manufacturing of usefulpharmaceutical drugs !Shah, "##$%
•Pharmaceutical supply chain more comple& !'hakoo and Chan ,"#((%)
• The Indian Pharmaceutical sector is highly fragmented withmore than "#,### registered units) Indian pharmaceuticalmarket is likely to grow at a compound annual growth rate!C+-% of ($.(/ per cent in between "#(".(0 in terms ofolume)
•India is now among the top ten pharmaceutical emergingmarkets of the world)
•Indian pharma industry is mainly operated as well as controlledby dominant foreign companies haing subsidiaries in India dueto aailability of cheap labor in India at lowest cost)
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 4/29
Critical Issues in 1anagingPharmaceuticals
• 1anaging perishable products
• 2egradation of the medicines as theymoe along the supply chain which
results in allowing substandard productsto be dispensed to the patients
• 1aintaining temperature control
• 1ore focus on -32• Shipping of e&piry products
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 5/29
Critical Issues in 1anagingPharmaceuticals
• In case of an epidemic break.out,global demand for certain medicinesoershoots the demand suddenly)
• Product withdrawal during sales dueto side.e4ects and e&piry
• 5ut of stock situations areunacceptable 3 patent lifespan is low
• Comple& 6etwork 2esign
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 6/29
Critical Issues in 1anagingPharmaceuticals
• Controlling wide supply chain withhuge Stock 7eeping 8nits becomesery di9cult
• Training 3 education cost to thestakeholders is high
• Integration of domestic andinternational businesses)
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 7/29
(he -alue Chain Cost Distriution
Value Chain Stages Cost Distribution
Research & Development Cost 15%
Primary Manufacturing cost 5 – 10%
econ!ary Mfg"Pac#aging 15 – $0 %
Mar#eting " !istriution 0 – 5%
'eneral (!ministration 5%
Profit $0%
Total 100 %
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 8/29
Pressures,
• To e4ectiely green the PSC i)e) correctly disposing of
e&pired:unwanted medications and reducing the leel ofpreentable pharmaceutical waste !'reen and ;ie, "##<%)
•Innoatie and enironmentally friendly medication designs!6onaka and Takeuchi ,(<<= , ;ie and 'reen, "#("%)
•Cleaner production methods:processes and green packaging
!>hu and Sarkis, "##$%)•?ean manufacturing principles for pharmaceuticale@uipment manufacturing rm to reduce waste in its shopAoor operation !+lbert ,"##$%
•2eelopment of decision support strategies and systems for
managing new product portfolios !Perez.Bscobedo et al),"#("%
•2eelopment of Trust among supply chain members andconsumers
!ausman and Stock, "##D%
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 9/29
Signicance of SC1 inPharmaceutical sector
B&cellent supply chain management canyieldE
• "=.=# reduction in total supply chain costs• "=.0# reduction in inentory holding
• "=.G# increase in forecast accuracy
• D#.=# improement in order.fullmentcycle time
• "# increase in after.ta& free cash Aows
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 10/29
Challenges•
To manage operational e&cellence in terms ofcost.e4ectie deelopment and faster lead.times!Pisano , "###%)
• B&penditure of high cost and time in conductingclinical trials with low success rate in productdiscoery and clinical 2eelopment, !?aHnez etal), "#("%)
• To improe Innoation rates in the industry!Talias, "##/%)
• 2rug prices rises as high as 0=# percent than theacceptable international standard in underdeeloped countries in addition to the lowaailability of cheap medicines in the market,
5 !"##<%)
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 11/29
Challenges• Inability to forecast accurately, lack of
incenties for maintaining stocks, ine9cientdistribution systems and pilferage of medicinesfor priate resale !ealth +ction Internationaland 5, "##<%)
• 1aJority of hospitals seem to hae outdatedinformation systems with inter.organizationalconnectiity !'urns,"##"%)
• Inentory costs in the health care sector aresubstantial and are estimated to be between(# and (G of net reenues !Karett,(<<G%)
• 2etermining optimal inentory leels in thepharmaceutical supply chain is a comple&
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 12/29
Challenges• 6P2 as more important issue than the accepted
need of high @uality, low cost, anddi4erentiation to e&cel in todayLs competitiemarket !6onaka and Takeuchi, (<<=%
• Muality standards are ery stringent !reeneand 5L-ourke, "##0%)
• 5ptimal process planning and scheduling is
crucial for the 2eelopment of 6ew Product!Perez.Bscobedo et al),"#("%)
• -eerse ?ogistic for e&pired medicines !;ie and'reen , "#("%)
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 13/29
Challenges
• -isks and uncertainties related to the
recoery of pharmaceutical drugs !Sriastaa, "##G%)
• To control potential impact ofpharmaceuticals that reaches lakes andriers ia sewage plants and other sources!6ew ampshire 2epartment of
Bnironmental Serices, "##<%
• Implementation of e.business practices inthe healthcare supply chain such as lack ofconsistenc and oor data ualit and lobal
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 14/29
C+SB ST82N F-51P+-1+CB8TIC+? SBCT5-
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 15/29
Prole of Company
• +'C ?imited was formed in the year (<$=. The rm used to import Pharmaceuticalformulations from Burope and distributethem in estern India
• +'C ?imited has three plants which arespread across 1aharashtra and oa inestern India
• These facilities are built in line with the 1C+.87 guidelines and in compliance with 51P re@uirements
• It manufactures a wide range of products)
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 16/29
Prole of Company !Contd%
• +'C ?imited has oer G## eld sta4s and ($##stockists) +'C ltd has emerged as the most suitablepartner and proider of C-+1S !Contract -esearchand 1anufacturing Serices% to its customers
globally)• The -32 Centre has three diisions iz)
Formulations, +ctie Pharmaceutical Ingredients 3Intermediates and -egulatory 3 IP- Cell surrounded
oer an area of /#,### s@ feet)• It has built a strong international presence across its
markets in 8S+, Burope, +sia, +frica, ?atin +mericaand other CIS countries
• It has set up a state.of.the.art -32 Centre at
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 17/29
S5T +nalysisStrength Weakness
• Cost competitiveness
• Well developed infrastructure
with strong manufacturing base
• Access to pool of highly trained
scientists, both in India and
abroad
• Strong marketing and
distribution network
• Low investments in innovative
R!
• Lack of strong linkages between
industry and academia
• "nable to maintain global
#uality standards
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 18/29
Opportunities Threats• Significant e$port potential
• %arketing alliances to sell
%&C products in domestic
market
• Contract manufacturing
arrangements with %&Cs
• 'otential for developing India as
a centre for international clinical
trials
• Supply of generic drugs to
developed markets
• 'roduct patent regime poses
serious challenge
• Lack of (ovt Support for R!
activities
• !rug price control order puts
unrealistic ceilings on product
prices and profitability
• %ore competitive global players
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 19/29
Initiaties Taken• Changing its role in the market from a
OContract 1anufacturer of Finished 2osageFormsO to a OComplete Solutions ProiderO)
• In order to manage operations, +'C ltd
was helped by multiple Fo&Pro based in.house applications)
• +'C ?td has also made e4orts forconseration of energy which includes .
a%Installation of = star rating +irconditioners and 1otors for plantmachineries)
c% Introduction to -ain water haresting
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 20/29
+ction Plan for improement
Step (. Primary 2istribution SetupStep ".Baluated e&isting C3F+ network
to setup independent C3F+ network
STBP D. 5ne company appointed as2istribution arm for the other
STBP $. Forecast from eld implemented
STBP =. Incoming ?ogistics
STBP 0. Transportation 3 Freight Cost
STBP /. Inentory leels
STBP G. IT Initiaties
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 21/29
Supply Chain Performance/rame0or1
S l Ch i P f I d
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 22/29
Supply Chain Performance Inde&SCM Coordination Issues References
Top management commitment Factors• Investment of time and money for resource
development)• *ocused communication system• Ready to adopt new technology• +mployees training and empowerment
• Investment in R!
Shin et al) -.../, Arshinder et al)
-..0/*isher 1223/, Arshinder et al)-..3/,Stanley et al) -..2/, (owen and4allon -..-/
Organizational Factors• Lean organi5ation structure• 6I4 environment and lean practices
• 7rgani5ation culture for SC implementation• Integration of functions with in the
organi5ation
%elton -..8/, 7thman and (hani-..0/(rittel and Wises -..9/,Arshinderet al) -..0/, Sawik -..2/, Sorooret al) -..2/
Mutual understanding Factors• Agreed vision and goals of members of supply chain• 4rust development in SC members• +ffective implementation of :oint replenishment and
forecasting decisions• Supply chain risk; reward sharing
Arshinder et al) -..3/, <ianchiand Saleh, -.1./, Aviv -..1/,Arshinder et al) -..0/, Cachonand Lariviere -..8/, Ryu and=ucesan -..2/
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 23/29
Flow of information Factors
• "se of information technology I4/ toolsand techni#ues
• Information sharing; e$change
• Sharing of data related to purchasing andsupplies
Arshinder et al) -..0/, Arshinderet al) -..3/, Cao et al) -..0/,Stanley et al) -..2/, %arek and
%alys5ek -..0/
Relationship and decision making Factors
• Long term relationship with suppliers•
Long term relationship with retailers• Collaborative decision making; planning
with SC members• Logistics network optimi5ation
!isny and 4owill -..>/, Arshinderet al) -..0/, Lyu et al) -.1./,Arshinder et al) -..0/, Cao et al)-..0/, Soroor et al) -..2/, Sawik-..2/, 7thman and (hani -..0/
Performance Factors• +fficiency• *le$ibility• Responsiveness• !rugs #uality
<eamon 1222/, 'ersson and7lhager -..-/, Lai et al) -..-/,<erry -..?/, Luning et al) -..-/,@an der Spiegel -..9/, @aleeva-..8/
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 24/29
Supply Chain B4ectieness Inde&
Issues2 )op management commitment* Mutual un!erstan!ing* +lo, ofinformation* Relationship an! !ecision ma#ing* -rgani.ational factors*
Responsiveness• 5n the basis of Cleeland et al) !(<G<% model, SC
e4ectieness inde& is gien as
S 3 4∑ 5i 6og # i
here S 3
SC e4ectieness inde& for company K
• i Coordination Factor• - -ank of Coordination Factor• 7 i Inerse -ank ! For i 0, If -(, 7 0, if -",
7 =%
• i eight assigned to particular CoordinationFactor
Q( !Strength%, when percentage score R0# !1ean alueRD%)
# !6eutral%, when percentage score is.
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 25/29
Supply Chain B4ectieness 1apping for Case Company
S ! Coordination Factors Fi"e Point #ikert Scale
1 - > 9 8 %ean
$ TopmanagementCommitment
Investment of time and money forresource development
%-)3
*ocused communication system %
Ready to adopt new technology %
+mployees training and empowerment %
& Mutual'nderstanding
Agreed vision and goals of members ofsupply chain
%>).
4rust development in SC members %
+ffective implementation of :ointreplenishment forecasting decisions
%
Supply chain risk; reward sharing %
( Flow ofInformation
"se of Information 4echnology I4/ toolsand techni#ues
%9 Information sharing; e$change %
Sharing of data related to purchasing andsupplies
%
Supply Chain B4ectieness 1apping for
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 26/29
Supply Chain B4ectieness 1apping forCase Company
) Relationship
and decisionmaking
Long term relationship with suppliers %>)-8Long term relationship with stockist %
Collaborative decision making; planningwith SC members
%
Logistics and network optimi5ation %
* OrganizationFactors
Lean organi5ation structure %>)38
and lean practices %
7rgani5ation culture for SCimplementation
%
Integration of functions with in the
organi5ation
%
+Performance
+fficiency %9)8
Innovations and &'! %
Responsiveness %
!rugs #uality %
I ustrat on or ea uat ng oor nat on
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 27/29
I ustrat on or ea uat ng oor nat onInde&
Sr) &o
)
Issues of coordination %ean Rank
InverseRank
i/
Logi
Weight Wi/
WiLogi
1) 4op managementcommitment
-)3 ? 1 .).. . .
-) %utual understanding >). 8 - .)>. . .).
>) *low of information 9 - 8 .)3. B1 .)3.
9) Relationship anddecision making
>)-8 9 > .)90 B1 .)90
8) 7rgani5ational factors >)38 > 9 .)?. B1 .)?.
?) 'erformance 9)8 1 ? .)30 B1 .)30
Coordination Inde, - C. - /0Wi #og 1i2- &*+
C l di
7/21/2019 Pharma Packaging
http://slidepdf.com/reader/full/pharma-packaging 28/29
Concluding-ecommendations
• Improing Forecasting +ccuracy
• -educing Inentory leels
• Improing Customer Sericing leels and
trust building• Increasing Information +ailability of all S78s
• 2eelopment of new product deelopmentcapability
• 6eed to deelop e4ectie performanceframework for pharmaceutical supply chainconsidering emergency situation